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Abstract
In addition to being the universal cellular energy source, ATP
is the primary reservoir for the neuromodulator adenosine.
Consequently, adenosine is produced during ATP-depleting
conditions, such as epileptic seizures, during which adenosine
acts as an anticonvulsant to terminate seizure activity and
raise the threshold for subsequent seizures. These actions
protect neurones from excessive ionic ﬂuxes and hence
preserve the remaining cellular content of ATP. We have
investigated the consequences of manipulation of intracellular
ATP levels on adenosine release and epileptiform activity in
hippocampal slices by pre-incubating slices (3 h) with creatine
(1 mM) and the combination of ribose (1 mM) and adenine
(50 lM; RibAde). Creatine buffers and protects the concen-
tration of cellular ATP, whereas RibAde restores the reduced
cellular ATP in brain slices to near physiological levels. Using
electrophysiological recordings and microelectrode biosensors
for adenosine, we ﬁnd that, while having no effect on basal
synaptic transmission or paired-pulse facilitation, pre-incuba-
tion with creatine reduced adenosine release during
Mg2+free/4-aminopyridine-induced electrographic seizure
activity, whereas RibAde increased adenosine release. This
increased release of adenosine was associated with an
attenuation of both the intensity and frequency of seizure
activity. Given the depletion of ATP after injury to the brain, the
propensity for seizures after trauma and the risk of epilepto-
genesis, therapeutic strategies elevating the cellular reservoir
of adenosine may have value in the traumatized brain. Ribose
and adenine are both in use in man and thus their combination
merits consideration as a potential therapeutic for the acutely
injured central nervous system.
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The energy budget of the brain is spent largely on the
re-establishment of ionic homeostasis associated with
synaptic transmission and neuronal signalling (Harris et al.
2012). The energy currency occurs in the form of adenosine
triphosphate (ATP), which, after its sequential dephospho-
rylation, gives rise to the neuromodulator adenosine
(Fig. 1). Adenosine reduces neuronal energy demand via
the adenosine A1 receptor-mediated inhibition of gluta-
matergic excitatory synaptic transmission and hyperpolar-
ization of post-synaptic neurones. (Dunwiddie and Masino
2001; Sebastiao and Ribeiro 2015). The accumulation of
extracellular adenosine thus reﬂects the situation where
energy demand has outstripped energy production and
where, as a neuroprotective strategy, energy demands
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associated with neuronal activity must be minimized until
as such time as ATP production resumed and/or ATP levels
restored.
Such situations commonly arise in acute pathological
conditions, for example cerebral ischaemia where ATP
depletion and the release of adenosine occurs very rapidly
after the onset of occlusion of a blood vessel in vivo, or the
removal of oxygen and glucose from the perfusing medium
in vitro (Dale and Frenguelli 2009; Pedata et al. 2016).
During seizure activity the extracellular accumulation of
adenosine (During and Spencer 1992; Dunwiddie 1999; Dale
and Frenguelli 2009) likely results from rapid, potentially
very local (Wall and Richardson 2015; Frenguelli and Wall
2016), intracellular depletion of ATP, as well as the
extracellular metabolism of ATP released in an activity-
dependent manner (Dale and Frenguelli 2009). Under both
these conditions, the activation of adenosine A1 receptors
suppresses neuronal activity in an attempt to minimize
cellular energy demand. The intersection of multiple ATP-
depleting and adenosine-releasing insults occurs with the
prevalence of seizures after both stroke (Chung 2014) and
traumatic brain injury (Rao and Parko 2015).
Such insults cost the brain dearly in terms of repeated
demands on the energy currency. This situation is exacer-
bated by the loss from the brain into the bloodstream of
adenosine and subsequent metabolites (Weigand et al. 1999;
Tian et al. 2017). One such metabolite is hypoxanthine,
which is utilized by one branch of the purine salvage
pathway (Ipata et al. 2011), the primary route by which
adenine nucleotides are synthesized in the brain (Fig. 1). The
loss of ATP metabolites from the brain thus robs the brain of
the substrates with which to resynthesize ATP and likely
explains both the prolonged depletion of cerebral ATP levels
after injury, and the greater impact of secondary insults, such
as spreading depolarization, on survival and prognosis
(Kirino 2002; Strong et al. 2002; Pearson et al. 2003; Toth
et al. 2016; Dreier et al. 2017; Frenguelli 2017).
We have previously shown that the provision of both the
sugar backbone and purine moiety of ATP (ribose and
adenine respectively; ‘RibAde’) restored the reduced ATP
levels in acutely prepared brain slices to values found in vivo
(zur Nedden et al. 2011). This likely occurred either via the
action of the purine salvage enzyme adenine phosphoribosyl-
transferase (EC 2.4.2.7) and the direct formation of AMP, or
via deamination of adenine to hypoxanthine and the action of
hypoxanthine phosphoribosyl-transferase (HPRT, EC
2.4.2.8). We have further shown that this elevated reservoir
of ATP translates into greater release of adenosine in response
to electrical stimulation of afferent ﬁbres (zur Nedden et al.
2011), and oxygen/glucose deprivation (OGD) in hippocam-
pal slices (zur Nedden et al. 2014). The enhanced adenosine
release, via the activation of adenosine A1 receptors, raised
the threshold for the induction of long-term potentiation (zur
Nedden et al. 2011), and both hastened and prolonged the
effects of brief OGD on excitatory synaptic transmission (zur
Nedden et al. 2014). In contrast, buffering the breakdown of
ATP with creatine reduced both adenosine release and the
depressant effects of OGD on synaptic transmission, but
delayed the anoxic depolarization and protected synaptic
transmission from prolonged OGD (zur Nedden et al. 2014).
Fig. 1 ATP metabolism and synthesis via the cytosolic purine salvage
pathway. Under conditions of energy depletion, ATP is metabolized to
adenosine (Ado), inosine (Ino), hypoxanthine (HX) and xanthine (X),
which can, via equilibrative transporters, leave cells and enter the
bloodstream. Direct cellular release of ATP and subsequent extracel-
lular metabolism by ectonucleotidases (not shown) provides another
source of extracellular adenosine and purine loss to the bloodstream.
Purine salvage (green arrows) restores adenine nucleotide levels via
adenine phosphoribosyl-transferase (APRT, EC 2.4.2.7; adenine to
AMP) and hypoxanthine phosphoribosyl-transferase (HPRT, EC
2.4.2.8; hypoxanthine to inosine monophosphate, IMP). This reaction
requires 5-phosphoribosyl-1-pyrophosphate (PRPP), a product of the
pentose phosphate pathway that gives rise to ribose-5-phosphate,
which can also arise from the isomerization of inosine-derived ribose-
1-phosphate (Rib-1-P) by phosphopentomutase (EC 5.4.2.7), and the
action of ribokinase (EC 2.7.1.15) on D-ribose. Creatine can be
converted to phosphocreatine (PCr), which acts as a phosphate donor
to ADP to regenerate ATP, thus buffering ATP levels and preventing
accumulation of ATP metabolites. 1, ATPases; 2, adenylate kinase
(EC 2.7.4.3); 3, cytosolic 50nucleotidase (EC 3.1.3.5); 4, adenosine
kinase (EC 2.7.1.20); 5, adenosine deaminase (EC 3.5.4.4); 6, purine
nucleoside phosphorylase (EC 2.4.2.1); 7, xanthine oxidase (EC
1.17.3.2); 8, ribokinase (EC 2.7.1.15); 9, phosphoribosylpyrophos-
phate synthetase (EC 2.7.6.1); 10, adenylosuccinate synthetase (EC
6.3.4.4); 11, adenylosuccinate lyase (EC 4.3.2.2); 12, creatine kinase
(EC 2.7.3.2). H2O2, hydrogen peroxide; UA, uric acid. Colour coding for
creatine (red) and D-ribose/adenine (blue) are used throughout the
data ﬁgures.
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In this study, we explored the release of adenosine during
in vitro seizure activity when the availability of intracellular
ATP is experimentally inﬂuenced by both creatine, which
buffers ATP decline, and RibAde, which elevates cellular
ATP levels. We ﬁnd that creatine resulted in reduced
extracellular adenosine release during epileptiform activity,
whereas RibAde increased the release of adenosine under
these conditions. These manipulations had consequences for
seizure activity in enhancing and reducing seizure activity
respectively. These ﬁndings demonstrate that the source of
extracellular adenosine during seizure activity likely arises, at
least in part, from the metabolic pool of ATP, that this pool is
reduced even during brief seizure activity, and that the pool
is amenable to manipulation to inﬂuence neuronal activity.
Moreover, these observations have implications for the
traumatized brain, in, for example the provision of RibAde
in the aftermath of injury to mitigate both the severity of




Creatine (C0780), D-ribose (R9629), adenine (A2786), adenosine
(A9251), 8-cyclopentyltheophylline (8-CPT; C102), 5-hydroxytryp-
tamine hydrochloride (5-HT; H9523) and 4-aminopyridine (4-AP;
275875) were purchased from Sigma Aldrich. 8-CPT was dissolved
in 0.1 M NaOH. Creatine, ribose and adenine were dissolved
directly into artiﬁcial cerebrospinal ﬂuid (aCSF). All salts for the
aCSF were purchased from Fisher Scientiﬁc.
Preparation of hippocampal slices
Seventy-four 17- to 23-day-old male Sprague–Dawley rats, obtained
form an in-house colony, were used. To minimize suffering, rats
were swiftly and humanely killed by cervical dislocation by a skilled
and competent researcher. Animal procedures were in accordance
with Schedule 1 of the UK Government Animals (Scientiﬁc
Procedures) Act 1986 and were performed with approval from the
University of Warwick Animal Welfare and Ethical Review Board
(AWERB.30/13-14). Animals were then decapitated and the brain
was quickly removed and placed in ice-cold aCSF containing (mM):
NaCl (124), KCl (3), CaCl2 (2), NaHCO3 (26), NaH2PO3 (1.23), D-
glucose (10) and MgSO4 (1) with an additional MgCl2 (10); pH 7.4.
Parasagittal hippocampal brain slices (400 lm) were cut on a
vibratome (Microm HM 650 V microtome) (zur Nedden et al.
2011; zur Nedden et al. 2014) and placed in 100 or 250 mL
incubation chambers in which aCSF circulated around the slices.
Slices were kept at 34°C and bubbled with 95% O2/5% CO2 for at
least 3 h before use (Edwards et al. 1989). Slices from a given
animal were incubated in either standard 1 mM Mg2+-containing
aCSF, or in a standard aCSF containing either 1 mM creatine, or
1 mM D-ribose plus 50 lM adenine (RibAde). While no formal
randomization in assigning slices to experimental treatments was
conducted, efforts were made to ensure that no systematic bias was
introduced by, for example assigning a particular hemisphere or
hippocampal location (dorsal, medial, ventral) to one experimental
condition. Experiments were not conducted blind to the experimen-
tal treatment, and the study was not pre-registered.
Electrophysiological recordings and drug application
Post recovery, slices were submerged in a recording chamber,
secured with a platinum harp with nylon threads and were perfused
with oxygenated aCSF at a rate of ~6.0 mL/min and maintained at
32–33°C. To ensure adequate perfusion of the slice, the slice was
placed upon a mesh platform that allowed aCSF to ﬂow below and
above the slice (Etherington and Frenguelli 2004). A twisted bipolar
Teﬂon-coated tungsten wire electrode (100 lm diameter) was
placed in stratum radiatum in area CA1. Extracellular ﬁeld
excitatory post-synaptic potentials (fEPSPs) were recorded with a
glass microelectrode ﬁlled with aCSF. Slices were stimulated prior
to the introduction of pro-convulsant aCSF to ensure slice viability
and stability of the recording, and to measure the effects of drugs on
basal synaptic transmission. Stimulus parameters and acquisition
and analysis of fEPSPs were under control of WinLTP software
(WinLTP, RRID:SCR_008590; (Anderson and Collingridge 2007)).
Epileptiform activity was captured and analysed using Spike2
software (Spike2 Software, RRID:SCR_000903; CED, Cambridge,
UK) running simultaneously with WinLTP on the same PC. All
pharmacological agents were bath-applied.
Biosensor recordings
Adenosine biosensors were used in these experiments to measure
the release of purines in real-time. Null biosensors, lacking the three
enzymes necessary to metabolize adenosine to hydrogen peroxide,
were used to detect the presence of electroactive interferents that
could have contaminated the signal on the adenosine sensor. The
signal from the null was subtracted from that of the adenosine
sensor.
Adenosine (SBS-ADO-05-50) and null (SBS-NUL-05-50)
biosensors (Pt/Ir wire of 50 lm in diameter and 500 lm in length)
were purchased from Sarissa Biomedical Ltd (Coventry, UK) and
were inserted into the slice in stratum radiatum of area CA1. The
adenosine biosensors encapsulate a speciﬁc enzymatic cascade that
metabolizes adenosine to produce hydrogen peroxide. The enzymes
(adenosine deaminase, EC 3.5.4.4; purine nucleoside phosphorylase,
EC 2.4.2.1 and xanthine oxidase, EC 1.17.3.2) are deposited on the
screening layer where they are entrapped in a polymer matrix as
described previously (Llaudet et al. 2003; Frenguelli and Wall
2016). Because of the nature of the enzymatic cascade present in the
adenosine biosensors they are also capable of detecting not only
adenosine but also its metabolites inosine, hypoxanthine and
xanthine. Null sensors contain no enzymes and measure only non-
speciﬁc electroactive signals. After each experiment, sensors were
withdrawn from slices and calibrated with 10 lM adenosine. The
values from adenosine biosensors are given as micromolar prime
(lM0) to reﬂect that the adenosine signal is a composite signal of
adenosine and its metabolites (Frenguelli et al. 2007). Because of
the highly localized nature of signals associated with epileptiform
activity in brain tissue, it is difﬁcult to consistently perform
differential recordings between an adenosine sensor and an inosine
sensor to yield a net adenosine signal (Wall and Richardson 2015;
Frenguelli and Wall 2016). However, when such differential
measurements between adenosine and inosine biosensors have been
made they have demonstrated that the majority of the signal detected
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on the adenosine sensor during seizure activity was indeed
adenosine (Etherington et al. 2009). The release of adenosine was
measured over a time period of 15 min in nominally Mg2+-free
aCSF, after the appearance of three bursts or 10 min in 4-AP, and
after 10 min in 8-CPT. Adenosine release associated with each burst
was measured over the duration of the burst, that is from the start of
the burst to its end; this likely underestimated the amount of release
per burst as release often continued after the end of the burst.
Release is given as the integral over these period of measurements in
units of lM0s.
To conﬁrm the patency of the biosensor electroactive interferent
screening layer, biosensors were perfused with 10 lM 5-HT.
Biosensor measurements were only accepted and further processed
if the biosensor current to 5-HT did not exceed 150 pA. The current
response of the simultaneously recorded null sensors was subtracted
from the adenosine signal to reveal a net purine signal, the majority of
which reﬂects the appearance of adenosine in the extracellular space
(Etherington et al. 2009) and is therefore referred to as adenosine.
Data analyses
Traces of extracellular epileptiform seizure activity were rectiﬁed,
and the following measurements made: burst duration; inter-burst
interval, and, within a burst, the inter-spike interval with the
threshold inter-spike interval being set to 50 ms to avoid double-
counting of rectiﬁed spikes. Bursting seizure activity was deﬁned
as periods of electrophysiological activity with intervening periods
of quiescence – the inter-burst interval. Bursting activity was
deemed to have stopped when the inter-spike interval became
> 1.5 s. Basal synaptic transmission measurements were made,
which included: fEPSP slope measurements during stimulus input/
output curves at 50 lA increments from 50 to 300 lA; the pre-
synaptic ﬁbre-volley amplitude at the highest stimulus strength of
300 lA; the ratio of fEPSP slopes for paired stimulus pulses given
50 ms apart, and the change in fEPSP slope associated with the
removal of Mg2+ from the aCSF. The integral of adenosine release
was measured for null-subtracted biosensor data and the values
expressed as lM0s.
Statistical analysis
Values are expressed as mean  SEM. N values represent number
of slices per condition, which in almost all cases is equivalent to the
number of animals per condition. No sample size calculations were
conducted. If more than two groups were to be assessed, a one-way
ANOVA was used. For comparison of fEPSP slope during input/output
curves, a two-way mixed-design ANOVA, with treatment as the
between-group factor and stimulus strength as the repeated-
measures factor, was applied. Where signiﬁcant differences were
found across the groups, post hoc Bonferroni comparisons were
made between groups. Graphs were drawn and statistical analyses
were performed in OriginPro 2016 software (OriginPro, RRID:
SCR_015636). Statistical signiﬁcance was taken as p < 0.05.
Results
Influence of creatine and RibAde on basal synaptic
transmission
Hippocampal slices were pre-incubated for at least 3 h in
standard aCSF, or aCSF supplemented with either creatine
(1 mM) or RibAde (1 mM ribose and 50 lM adenine).
Thereafter, slices were placed in a recording chamber and
perfused with standard aCSF. Despite there being a trend for
creatine-treated slices to show stronger synaptic transmis-
sion, there was no signiﬁcant main effect of treatment on the
stimulus input/output curves (Fig. 2a; two-way mixed-design
ANOVA (treatment and stimulus strength) F2,127 = 1.202;
p = 0.275). Treatment did not affect either the size of the
pre-synaptic ﬁbre volley (Fig. 2b; measured at 300 lA
stimulus strength; one-way ANOVA; F2,33 = 0.942;
p = 0.400), or the paired-pulse facilitation ratio measured
at an inter-pulse interval of 50 ms (Fig. 2c; one-way ANOVA;
F2,107 = 2.49; p = 0.088). These data suggest that neither
creatine nor RibAde affect pre-synaptic function (axonal
excitability and the probability of glutamate release respec-
tively) or the post-synaptic response to glutamate and are
consistent with our previous observations (zur Nedden et al.
2011; zur Nedden et al. 2014).
After a period of baseline recording of the electrically
evoked fEPSP, the aCSF was changed to one to which no
Mg2+ was added (Mg2+-free aCSF) in order to alleviate the
Mg2+ block of the NMDA receptor and to increase tissue
excitability (Etherington and Frenguelli 2004; Etherington
et al. 2009; Lopatar et al. 2011). This manipulation caused
an enhancement in the slope of the fEPSP, which was similar
across the various treatments (Fig. 2d; creatine = 272.7 
18.4%, n = 19; control = 276.2  9.0%, n = 51; RibAde =
270.3  11.9%, n = 32; F2,99 = 0.076; p = 0.927).
Bidirectional modulation of adenosine release during
epileptiform activity by creatine and RibAde
Perfusion of hippocampal slices with Mg2+-free aCSF
provoked adenosine release (Lopatar et al. 2011) (Fig. 3).
The adenosine release in Mg2+-free aCSF was not signif-
icantly different across the three groups (Fig. 4a; one-way
ANOVA, F2,29 = 3.238; p = 0.054), but with a trend towards
greater release in RibAde-treated slices (0.44  0.12
lM0s, n = 13) and least in slices pre-incubated with
creatine (0.13  0.02 lM0s, n = 8). Control slices showed
intermediate release of adenosine (0.23  0.04 lM0s,
n = 11).
Since Mg2+-free aCSF did not consistently result in
electrographic seizure activity, we added 4-AP (50 lM),
which provokes epileptiform activity by blocking K+
channels and promoting neuronal depolarization (Avoli
and Jefferys 2016). 4-AP caused the appearance of bursting
seizure activity and additional adenosine release (Figs 3
and 4b). This release was signiﬁcantly different across the
three groups (one-way ANOVA, F2,29 = 7.701; p = 0.002),
and in RibAde-treated slices (3.15  0.53 lM0s, n = 13)
compared to both control (1.49  0.28 lM0s; one-way
ANOVA with post hoc Bonferroni test, p = 0.018; n = 11)
and creatine-treated slices (0.95  0.18 lM0s; one-way
ANOVA with post hoc Bonferroni test, p = 0.004, n = 8).
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Fig. 2 Inﬂuence of RibAde and creatine on excitatory synaptic trans-
mission. (a) Input-output curves of ﬁeld excitatory post-synaptic
potential (fEPSP) slope versus stimulus strength (mean  SEM) for
control (black line and symbols; n = 56 slices) and creatine- (red;
n = 28 slices) and RibAde-treated slices (blue; n = 47 slices). Inset are
representative fEPSPs at increasing stimulus strengths from each of
the three conditions and colour-coded as per the graph. There was no
main effect of treatment on the input-output curves (ns; p = 0.275)
Scale bars measure 0.5 mV and 5 ms. (b) No signiﬁcant difference (ns;
p = 0.400) was observed in the pre-synaptic ﬁbre volley (measured at
300 lA stimulus strength; data from 9 to 17 slices) across the three
conditions. The graph plots individual ﬁbre volley amplitude for each
experiment and condition with the mean for each depicted as a
horizontal bar. Inset traces show representative ﬁbre volleys indicated
by an arrow and colour-coded as per the graph. fEPSPs have been
truncated at 5 ms after the onset of electrical stimulation (ﬁrst
downward deﬂection for each trace) and show the positive-going
population spike occasionally evoked at high (300 lA) stimulus
strengths. Scale bar measures 0.5 mV and 1 ms. (c) Paired-pulse
facilitation was not inﬂuenced by RibAde or creatine (p = 0.088). The
graph plots individual paired-pulse ratios (50 ms inter-pulse interval;
n = 22–47 slices) for each experiment and condition with the mean for
each depicted as a horizontal bar. Inset is the representative fEPSPs,
evoked at 50 ms intervals, colour-coded as per the graph. Scale bars
measure 0.5 mV and 25 ms. (d) The enhancement of synaptic
transmission caused by removal of Mg2+ from the artiﬁcial cere-
brospinal ﬂuid (aCSF) was not different in creatine- or RibAde-treated
slices compared to control slices (p = 0.927). The graph plots the
maximal enhancement of the fEPSP after 15 min exposure to nomi-
nally Mg2+-free aCSF (n = 19–51 slices) for each experiment and
condition, with the mean for each depicted as a horizontal bar. Inset is a
representative experiment showing the enhancement of the fEPSP (as
a percentage of baseline) after removal of Mg2+ from the aCSF, which
occurred at t = 10 min (broken vertical line).
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Since each burst of seizure activity provoked the release of
adenosine, we measured the release of adenosine during each
of the three bursts (Fig. 4c). That the release of adenosine
occurred in an activity-dependent manner was evidenced by
the fact that there was a linear correlation between seizure
duration and adenosine release (r = 0.406, p = 0.0002,
n = 82 bursts; data not shown). An analysis of release
within each burst showed that while the release of adenosine
during bursts 1, 2 and 3 were similar and consistent within
creatine-treated and control slices, RibAde selectively and
signiﬁcantly (one-way ANOVA: F2,29 = 8.527; p = 0.001)
enhanced adenosine release during the ﬁrst of the three bursts
(2.43  0.51 lM0s, n = 13) compared to control (0.66 
0.18 lM0s; n = 11; post hoc Bonferroni: p = 0.005) and
creatine-treated slices (0.48  0.11 lM0s, n = 8; post hoc
Bonferroni test: p = 0.005). The fact that greatest release
occured only during the ﬁrst seizure burst in RibAde-treated
slices suggests that there is a rapidly depleting pool of
releasable adenosine (Pearson et al. 2001; Dale and
Frenguelli 2009). Attempts to address this by the continuous
perfusion of ribose and adenine during the recording (as
opposed to only during pre-incubation) did not alter the
proﬁle of burst-induced adenosine release, with more
adenosine being released only during the ﬁrst burst
(2.54  0.65 lM0s; n = 8; data not shown), suggesting that
the interval between bursts (~1–2 mins) was not sufﬁcient to
allow replenishment of the ATP-derived releasable adenosine
pool.
The adenosine A1 receptor antagonist 8-CPT (1 lM) was
added after slices had displayed three periods of bursting
seizure activity, or after 10 mins had elapsed in 4-AP (Fig. 3)
to remove the inhibitory tone caused by ambient adenosine and
to thus encourage further epileptiform activity. The addition of
8-CPT provoked a conversion of bursting seizure activity to
continuous spike ﬁring, as described previously (Lopatar et al.
2015), and further adenosine release, the extent of which did
Fig. 3 RibAde increased, whereas creatine decreased adenosine
release during seizure activity, consistent with their ability to elevate
the cellular ATP pool and buffer ATP decline respectively. Upper
traces show adenosine release in Mg2+-free artiﬁcial cerebrospinal
ﬂuid (aCSF), the K+ channel blocker 4-AP (50 lM), and the adenosine
A1 receptor antagonist 8-CPT (1 lM) in control (black trace; n = 11)
and creatine- (red trace; n = 8) and RibAde-treated slices (blue trace;
n = 13). Traces show the averages of between 8 and 13 experiments.
The break in the graph between 4-AP and 8-CPT reﬂects the time
between the end of either three 4-AP-induced bursting episodes or 10
mins in 4-AP, and the start of 8-CPT application. The time in 4-AP thus
varied across slices and necessitated synchronization to the time of 8-
CPT application. The lower AC-coupled electrophysiological trace
shows representative synaptic and epileptiform activity associated with
the perfusion of slices with Mg2+-free aCSF, 4-AP and 8-CPT. Mg2+-
free aCSF causes an enhancement of the ﬁeld excitatory post-synaptic
potential (fEPSP) (Fig. 2d; periodic downward deﬂections on the
trace), which is occasionally curtailed by the rise in extracellular
adenosine and the resulting inhibition of the fEPSP (as in this case;
see also Lopatar et al. 2011). After 15 min in Mg2+-free aCSF electrical
stimulation was stopped and 4-AP was then perfused in the continued
absence of extracellular Mg2+. 4-AP-induced bursting activity inter-
rupted by periods of electrical quiescence (the inter-burst interval).
After either three bursts in 4-AP or 10 min, 8-CPT was perfused (in
Mg2+-free and 4-AP-containing aCSF). 8-CPT converted the discrete
bursting in 4-AP to sustained ﬁring indicating the high inhibitory
adenosine tone in slices.
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Fig. 4 Quantiﬁcation of adenosine release in control and creatine- and
RibAde-treated slices. Area under the curve measurements were
made: (a) over 15 min for the adenosine release during initial washout
of Mg2+ from the slice (n = 8–13 slices); (b) after either three bursts or
10 min in 4-AP (n = 8–13 slices); (c) in response to each seizure burst
(n = 8–13 slices); (d) during challenge with 8-CPT (n = 8–12 slices),
(e) over the total adenosine release under each of these conditions
(n = 8–13 slices). Data are shown from individual experiments, with
the mean for each condition and treatment given as the horizontal line.
(a) There was no overall group difference in adenosine release in
Mg2+-free artiﬁcial cerebrospinal ﬂuid (aCSF) (p = 0.054), but with a
trend towards RibAde-treated slices releasing most adenosine, and
creatine-treated slices releasing the least. (b) Signiﬁcant differences in
adenosine release were observed in the presence of 4-AP, in RibAde-
treated slices compared to both control (p = 0.018; *) and creatine-
treated slices (p = 0.004; **). (c) Individual burst-induced adenosine
release was greatest during burst 1 in RibAde-treated slices compared
to both control (p = 0.005; **) and creatine-treated slices (p = 0.005;
**). Subsequent bursts 2 and 3 showed no signiﬁcant differences (ns)
in release between control slices and slices pre-treated with either
RibAde or creatine. (d) Although 8-CPT further increased the amount
of adenosine released from slices, this additional release was not
signiﬁcantly different (ns) between treatments (p = 0.846). (e) The total
combined release per slice was signiﬁcantly greater in RibAde-treated
slices compared to creatine-treated slices (p = 0.025; *) and control
slices (p = 0.013; *).
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not differ among the three groups (Fig. 4d; F2,25 = 0.168,
p = 0.846; creatine = 1.76  0.23 lM0s, n = 8; con-
trol = 1.55  0.21 lM0s, n = 8; RibAde = 1.77  0.31
lM0s, n = 12).
Overall (the sum of release in Mg2+-free, 4-AP and 8-CPT
conditions; Fig. 4e), RibAde-treated slices released more
adenosine (5.22  0.75 lM0s, n = 13; one-way ANOVAs,
F2,29 = 6.19, p = 0.006) than control (2.85  0.32 lM0s,
n = 11; Bonferroni post hoc test, p = 0.013) and creatine-
treated slices (2.84  0.26 lM0s, n = 8; Bonferroni post hoc
test, p = 0.025). This analysis also held true if only those
slices exposed to all three experimental manipulations
(Mg2+-free, 4-AP and 8-CPT) were considered (one-way
ANOVAs, F2,25 = 5.818, p = 0.008; data not shown).
Slices in which RibAde was continuously perfused
throughout this period released even more adenosine
(8.33  1.17 lM0s; n = 8; not shown). This latter observa-
tion suggests that, over the time-course of these experiments
(~30 mins), the replenishment of an adenine nucleotide pool
that contributes to activity-dependent adenosine release can
occur. This has potential implications for conditions, such as
TBI, where post-traumatic seizures can persist for prolonged
periods and may initiate epileptogenesis.
Creatine and RibAde influence seizure activity by regulating
the availability of extracellular adenosine
To establish whether the modulation of adenosine release by
creatine and RibAde inﬂuenced seizure activity we measured
a number of parameters of the bursting activity evoked by
Mg2+/4-AP: duration of seizure bursts (Fig. 5a), the inter-
spike interval during a burst (Fig. 5b), and the time between
bursts, the inter-burst interval (Fig. 5c).
Neither creatine nor RibAde inﬂuenced the duration of the
ﬁrst, second or third seizure bursts (Fig. 5a; one-way
ANOVAs, F2,83 = 0.166, p = 0.848; F2,65 = 1.954, p =
0.150; F2,51 = 0.124, p = 0.883 respectively). Within each of
the three bursts, RibAde increased the inter-spike interval (i.e.
reduced burst intensity) compared to creatine only during the
ﬁrst burst, where greatest release of adenosine was observed
(Fig. 4c, 5b; one-way ANOVA, F2,83 = 3.728, p = 0.028, post
hoc Bonferroni RibAde vs. creatine, p = 0.023). To test
whether creatine and RibAde had an effect on the frequency
at which bursting occurred, the inter-burst interval was
measured (Fig. 5c). The time of occurrence of the second
burst (Inter-Burst Interval 1) in RibAde slices was delayed
(107.8  9.3 s) compared to both creatine-treated (61.2 
7.4 s; Post hoc Bonferroni: p < 0.0001) and control slices
(76.5  5.8 s; post hoc Bonferroni: p = 0.018; one-way
ANOVA: p < 0.0001; F2,65 = 8.983). Similarly, the time to the
third burst (Inter-Burst Interval 2) was increased (one-way
ANOVA: p = 0.008; F2,50 = 5.398) in RibAde-treated slices
(93.2  8.4 s) compared to creatine (63.9  7.6 s; post hoc
Bonferroni: p = 0.031) and control slices (63.5  5.8 s; post
hoc Bonferroni: p = 0.019).
Discussion
We have shown that the accumulation of extracellular
adenosine during brief seizure activity is dependent upon
the availability and metabolism of intracellular ATP. This
observation in itself suggests that synapses are under
autonomous, spatially restricted, activity-dependent control
that is determined by local cellular ATP levels and its rapid
metabolism to adenosine. Moreover, we show that the
availability of ATP can be modulated pharmacologically.
Fig. 5 Seizure frequency and intensity, but not duration, is inﬂuenced
by pre-incubation with creatine and RibAde. (a) The duration of 4-AP-
induced bursts was not signiﬁcantly different (ns) between the three
treatments (Burst 1: p = 0.848, n = 24–32 slices; Burst 2: p = 0.150,
n = 19–27 slices; Burst 3: p = 0.883, n = 15–22 slices). (b) Treatment
inﬂuenced the inter-spike interval in Burst 1 (p = 0.028), with a
signiﬁcant difference between RibAde- and creatine-treated slices
(p = 0.023; *), but with no inﬂuence on Bursts 2 or 3. (c) Inter-burst
interval was sensitive to the treatments. RibAde delayed the occur-
rence of Burst 2 (Inter-Burst Interval 1; n = 19–27) compared to both
creatine-treated (p < 0.0001; ****) and control slices (p = 0.018; *).
Burst 3 (Inter-Burst Interval 2; n = 15–22) was also delayed in RibAde-
treated slices compared to both creatine-treated (p = 0.031; *) and
control slices (p = 0.019; *).
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This may be of value in conditions characterized by ATP
depletion where ATP levels, and the reservoir for the
anticonvulsant adenosine, may be restored via the provision
of ribose and adenine.
Restoration of cellular ATP via the purine salvage
pathway
The brain, like the heart, relies upon the purine salvage
pathway for the synthesis of adenine nucleotides (Ipata et al.
2011; Frenguelli 2017). This synthesis initially occurs in the
form of AMP, either through the actions of adenine phospho-
ribosyl-transferase and HPRT on nucleotide precursor mole-
cules, or via the action of adenosine kinase (EC 2.7.1.20) on
adenosine (Fig. 1). While this route is rapid, energetically
efﬁcient, occurs in the cytosol and can deliver ATP to remote
neuronal regions lacking mitochondria such as dendritic
spines; (Kasthuri et al. 2015; Babits et al. 2016), it is
constrained by the availability of salvageable substrates.
Under normal circumstances this constraint is met, and
substrates are available in sufﬁcient quantities to meet the
demand for ATP. However, under conditions of ATP deple-
tion, most notably cerebral ischaemia, ATP is metabolized to
compounds that are lost to the circulation, or, in the case of
xanthine, beyond salvage (Weigand et al. 1999; Frenguelli
2017; Tian et al. 2017). This loss of salvageable substrates,
together with injury-induced mitochondrial dysfunction, and
indeed potential ATP consumption by mitochondria, likely
explains the profound and protracted depletion of cerebral
ATP after various forms of injury (Frenguelli 2017).
Using hippocampal slices as a model of the post-traumatic,
post-ischaemic brain (Hossmann 2008) we previously showed
that providing slices with the ATP precursors ribose and
adenine (RibAde) resulted in an elevation of tissue ATP to
levels found in vivo (zur Nedden et al. 2011; zur Neddenet al.
2014). Moreover, this elevation of cellular ATP increased the
reservoir for adenosine, which was released in greater
quantities during high-frequency stimulation of afferents (zur
Nedden et al. 2011) and during oxygen/glucose deprivation
(OGD) (zur Neddenet al. 2014). Creatine, on the other hand,
did not elevate tissue ATP, but did preserve cellular ATP
during OGD and, as a consequence, reduced adenosine release
(zur Neddenet al. 2014). In this study, using the concentra-
tions and duration of application of RibAde and creatine
described previously, we conﬁrmed the bidirectional modula-
tion of adenosine release by RibAde and creatine, which we
have previously shown by HPLC was because of elevation
and preservation, respectively, of cellular ATP (zur Nedden
et al. 2011; zur Neddenet al. 2014). We have also conﬁrmed
that these manipulations do not affect basal synaptic trans-
mission, paired-pulse facilitation or the pre-synaptic ﬁbre
volley; their inﬂuence is therefore only likely to be manifest
under conditions of ATP depletion, in the present case during
epileptiform activity.
Seizure activity-dependent adenosine release
Removal of extracellular Mg2+ favours both activation of
post-synaptic NMDA receptors and promotes glutamate
release. As such it is commonly used as a means to increase
the excitability of neuronal tissue (Mody et al. 1987). This
excitation is tempered by the NMDA receptor-dependent
release of adenosine (Manzoni et al. 1994), which we have
previously been able to observe directly using adenosine
biosensors (Lopatar et al. 2011). In this study, there was a
tendency for the release of adenosine in Mg2+-free aCSF to
be bidirectionally inﬂuenced by both RibAde and creatine,
with greater release of adenosine in RibAde-treated slices,
and less release from slices pre-incubated in creatine. These
observations are consistent with the ability of these com-
pounds to elevate and buffer cellular ATP, respectively.
Inclusion of the K+ channel blocker 4-AP in the Mg2+-free
aCSF resulted in the appearance of bursting epileptiform
activity (Avoli and Jefferys 2016). This manipulation pro-
voked further adenosine release, which was similarly inﬂu-
enced by creatine (reduced) and RibAde (increased). An
analysis of adenosine release on a burst-by-burst basis showed
that, while consistent release was observed across the three
bursts in creatine-treated and control slices, RibAde-treated
slices released substantially more adenosine on the ﬁrst burst,
before releasing similar levels of adenosine during the
subsequent two bursts. This observation is consistent with
the concept of a depletable pool of adenosine that we have
described previously (Pearson et al. 2001) and implies that
there is a readily releasable pool of adenosine, most likely in
the formof intracellularATP,which, once released, takes some
time to be replenished. Indeed, attempts to replenish this pool
between burstswith continuous presentation of RibAde did not
affect the proﬁle of burst-induced adenosine release, suggest-
ing that the 1–2 min inter-burst interval is not sufﬁcient time
for replenishment to occur, even in the presence of substrate.
Previous successful attempts to replenish the adenosine pool
have involved prolonged intervals between challenges, the
provision of exogenous adenosine, and b adrenoceptor
activation (Pearson et al. 2001; Pearson and Frenguelli
2004; Dale and Frenguelli 2009). The ability to restore
adenosine release suggests that adenosine depletion does not
reﬂect an irreversible or pathological condition, but more
likely a diminution of locally available ATP or its precursors.
Indeed, in this study, slices continuously perfused with
RibAde released more adenosine overall than did slices that
had only been pre-incubated in RibAde, suggesting that over
the time-course of these experiments the releasable pool of
adenosine can be replenished.
The adenosine A1 receptor antagonist 8-CPT converted 4-
AP-induced bursting activity into regular spiking. This
implies that the duration and timing of bursts is regulated
by the burst-by-burst release of adenosine and the subsequent
activation of A1 receptors. Such conversions from bursting to
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regular spiking have been observed previously in vitro
(Avsar and Empson 2004; Lopatar et al. 2015) and have
been described as akin to entry into a status epilepticus-like
state (Avsar and Empson 2004). In vivo, knockout of
adenosine A1 receptors leads to fatal status epilepticus after
both intra-hippocampal kainic acid (Fedele et al. 2006) and
traumatic brain injury (Kochanek et al. 2006). In humans,
the adenosine receptor antagonist theophylline can precipi-
tate status epilepticus (Kohl et al. 2011). These observations
indicate the importance of adenosine A1 receptors in limiting,
localizing and terminating seizure activity.
The increased spiking caused by 8-CPT resulted in
greater adenosine release, but the quantities released did not
differ across the three treatment groups. It is somewhat
surprising that more adenosine was not released in RibAde-
treated slices during 8-CPT since there was more adenosine
release in these slices during both Mg2+-free and Mg2+-free/
4-AP perfusion. It is possible that the larger quantities of
adenosine released previously depleted the releasable pool
of adenosine described above. Nonetheless, the total
quantity of adenosine release was greater in RibAde-treated
slices, and yet more was released from slices continuously
perfused with RibAde. This latter observation does suggest
that there may be value in providing the injured brain with
the substrates to make ATP and thus to boost the cellular
reservoir of the endogenous anticonvulsant adenosine.
Modulation of intracellular ATP influences
epileptiform activity
Wehave previously shown that pharmacological modulation of
intracellular ATP inﬂuences adenosine release, and through this
both synaptic transmission and synaptic plasticity. Pre-treat-
ment of hippocampal sliceswithRibAde raised the threshold for
the induction of long-term potentiation in a manner that was
dependent upon the activation of adenosine A1 receptors (zur
Nedden et al. 2011), whereas the depressant effects of OGD on
hippocampal synaptic transmission, which are known to be
largely dependent upon adenosineA1 receptors both in vitro and
in vivo (Fowler 1990; Gervitz et al. 2001; Dale and Frenguelli
2009), were enhanced by RibAde (zur Neddenet al. 2014). In
contrast, as has been observed by others (Whittingham and
Lipton 1981; Okada and Yoneda 1983), creatine delayed the
depression of synaptic transmission by OGD (zur Neddenet al.
2014). This is consistent with the better preservation of cellular
ATP and the reduced efﬂux of adenosine, rather than, as has
been proposed, better maintenance of cellular ATP per se. The
preservation of cellular ATP by creatine did, however, delay the
appearance of the anoxic depolarization and allowed the
recovery of synaptic activity after prolonged OGD (zur
Neddenet al. 2014), conﬁrming previous in vivo and in vitro
observations of the beneﬁts of creatine (Krivanek et al. 1958;
Whittingham and Lipton 1981; Okada and Yoneda 1983;
Balestrino 1995; Balestrino et al. 1999).
In this study we considered the actions of creatine and
RibAde on electrographic epileptiform activity. We measured
three parameters relating to 4-AP-induced seizure activity:
burst duration; inter-spike interval and inter-burst interval. We
found that neither creatine nor RibAde inﬂuenced the duration
of the three bursts evoked by 4-AP. This is somewhat
surprising given the differential effects of these manipulations
on adenosine release, and the importance of adenosine A1
receptors in terminating the bursts (see above). One possible
explanation is that even under conditions of restricted ATP
metabolism (by creatine) sufﬁcient adenosine is released to
terminate seizures; any additional release in RibAde-treated
slices is supramaximal and thus has no additional beneﬁt in
seizure termination. However, this is not to say that this
additional release is without effect; a comparison of the inter-
spike intervals within each burst showed that RibAde slowed
the frequency with which spikes occurred within the ﬁrst burst
– the burst during which greatest adenosine release was
observed in RibAde-treated slices. Thus, while the duration of
the burst is unaffected, the intensity of the burst is reduced.
Moreover, the interval between the bursts was increased by
RibAde, thereby reducing the frequency with which bursts
appear. This is consistent with the greater accumulation of
adenosine caused by a burst taking longer to return to a level
below the threshold for subsequent burst initiation.
Therapeutic implications of pharmacological
modulation of cellular ATP
There has been considerable interest in creatine as a
neuroprotective agent. This has arisen through a number of
in vitro and preclinical studies showing: creatine-mediated
restoration of cerebral phosphocreatine (Thomas 1956;
Whittingham and Lipton 1981; Yoneda et al. 1983); preser-
vation of neuronal membrane potential in the face of
metabolic stress (Krivanek et al. 1958; zur Neddenet al.
2014) recovery of synaptic function after OGD (Whitting-
ham and Lipton 1981; Okada and Yoneda 1983; Balestrino
1995; Balestrino et al. 1999; zur Neddenet al. 2014), and
neuroprotective beneﬁts of creatine following pre-treatment
in vivo (Andres et al. 2008; Balestrino et al. 2016). Pre-
treatment is necessary given the lack of creatine transporters
on astrocytic endfeet, which surround cerebral blood vessels
and thus hamper ingress of creatine (Andres et al. 2008;
Balestrino et al. 2016). This limitation in the potential of
creatine as a therapy has led to both the development of more
cell-permeable derivatives of creatine and calls for prophy-
lactic therapy for individuals at high risk of brain injury, for
example as a consequence of stroke (Balestrino et al. 2016).
Alternatively, we have proposed the use of ribose and
adenine, either alone or in combination with a xanthine
oxidase inhibitor, to improve outcome after brain injury
(Frenguelli 2017). In a rodent model of ischaemic stroke,
RibAde, when given intravenously for 6 hr during
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reperfusion, showed an encouraging trend to reduce brain
lesion volume and accelerate recovery of function in the
week after the period of cerebral ischaemia (Faller et al.
2017). Inclusion of a single intra-peritoneal injection of the
xanthine oxidase inhibitor, allopurinol (‘RibAdeAll’),
resulted in protection of a larger volume of brain tissue
(Faller et al. 2017). This enhancement by allopurinol may
reﬂect: reduced production of non-salvageable xanthine
allowing more hypoxanthine for salvage and ATP synthesis;
reduction in the production of reactive oxygen species
derived from hydrogen peroxide, or a direct anti-oxidant
action of allopurinol or its active metabolite oxypurinol (Juul
and Ferriero 2014; Frenguelli 2017).
Given that: (i) ribose has been used in man as an
unregulated nutritional supplement and as an aid to cardiac
rehabilitation and exercise performance (Bayram et al. 2015;
Seifert et al. 2017); (ii) adenine is added to blood transfusion
products as erythrocytes lack mitochondria and synthesize
ATP via purine salvage, and (iii) allopurinol has been in use
for the treatment of gout since the 1960s, suggests that the
combination of these compounds are likely to be well-
tolerated by humans and may form the basis of a readily
deliverable treatment for the hyper-acute management of
brain injury.
Conclusions
We have shown that the combined application of ribose and
adenine (RibAde) promoted greater accumulation of extra-
cellular adenosine during electrographic seizures in hip-
pocampal slices. This resulted in a reduction in the intensity
and frequency of epileptiform activity. These observations,
together with our previous studies in vitro and in vivo in a
rodent stroke model, and their safe use in humans, suggest
that ribose and adenine, together with allopurinol, may be of
value in the acutely injured brain.
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